<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189705</url>
  </required_header>
  <id_info>
    <org_study_id>037-402-00039</org_study_id>
    <nct_id>NCT04189705</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Phase 3 Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3&#xD;
      study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To contribute greater treatment compliance and patient convenience, the rebamipide SR&#xD;
      formulation has been developed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2019</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">April 23, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic Improvement Rate</measure>
    <time_frame>2 weeks</time_frame>
    <description>The percentage of subjects with improvement refer to those with more than 50% improvement in erosion score on gastroscopy after treatment compared to the score before treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Acute Gastritis</condition>
  <condition>Chronic Gastritis</condition>
  <arm_group>
    <arm_group_label>MCT-SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: MCT-SR 2 times/day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucosta Tab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Mucosta Tab. 3 times/day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCT-SR</intervention_name>
    <description>Rebamipide 150mg</description>
    <arm_group_label>MCT-SR</arm_group_label>
    <arm_group_label>Mucosta Tab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucosta Tab.</intervention_name>
    <description>Rebamipide 100mg</description>
    <arm_group_label>MCT-SR</arm_group_label>
    <arm_group_label>Mucosta Tab.</arm_group_label>
    <other_name>Mucosta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males and females aged â‰¥19 and &lt;75 years&#xD;
&#xD;
          -  Patients diagnosed with acute or chronic gastritis by gastroscopy with at least 1&#xD;
             erosion confirmed by gastroscopy within 7 days prior to the first dose of the&#xD;
             Investigational Product(IP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients ineligible for gastroscopy&#xD;
&#xD;
          -  Patients who took other drugs for treating gastritis within 2 weeks prior to the first&#xD;
             dose of the IP.&#xD;
&#xD;
          -  Patients who have to continue taking drugs that may induce gastritis&#xD;
&#xD;
          -  Other clinically significant medical or psychiatric findings that the investigator&#xD;
             considers inappropriate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JaeGyu Kim, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

